Vesicular monoamine transporter

Neurocrine Biosciences to Present New Data from its Movement Disorder Programs for Tardive Dyskinesia and Parkinson's Disease at Upcoming Scientific Meetings

Retrieved on: 
Thursday, September 3, 2020
Branches of biology, Neurological disorders, Organ systems, RTT, Syndromes, Tardive dyskinesia, Neurocrine Biosciences, Valbenazine, Parkinson's disease, Tardive, Vesicular monoamine transporter, Antipsychotic

"We are excited to present new data at this year's Psych Congress and MDS that illustrate the depth and breadth of our movement disorder programs for tardive dyskinesia and Parkinson's disease in clinical research," said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences.

Key Points: 
  • "We are excited to present new data at this year's Psych Congress and MDS that illustrate the depth and breadth of our movement disorder programs for tardive dyskinesia and Parkinson's disease in clinical research," said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences.
  • VMAT2 is a protein in the brain that packages neurotransmitters, such as dopamine, for transport and release in presynaptic neurons.
  • Additionally, INGREZZA can be taken for the treatment of tardive dyskinesia as one capsule, once-daily, together with psychiatric medications such as antipsychotics or antidepressants.
  • The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, with three pivotal and five mid-stage clinical programs in multiple therapeutic areas.

Kaden Health Announces the Commencement of Telehealth Services for Opioid Use Disorder in New Jersey

Retrieved on: 
Thursday, July 9, 2020
Branches of biology, RTT, Biochemistry, Substance dependence, Opioid use disorder, Vesicular monoamine transporter

NEW YORK, July 9, 2020 /PRNewswire-PRWeb/ -- Kaden Health, Inc. announced today that the company will begin providing virtual treatment services for Opioid Use Disorder for people living in New Jersey effective immediately.

Key Points: 
  • NEW YORK, July 9, 2020 /PRNewswire-PRWeb/ -- Kaden Health, Inc. announced today that the company will begin providing virtual treatment services for Opioid Use Disorder for people living in New Jersey effective immediately.
  • Kaden's Virtual Medication Assisted Treatment (vMAT) program is a fully integrated approach to treating those suffering from Opioid Use Disorder.
  • "We are incredibly excited to bring the benefits of the Kaden vMAT program and platform to the people of New Jersey.
  • Kaden is commencing its New Jersey launch in coordination with Horizon Healthcare Services, Inc. (Horizon), New Jersey's largest and oldest health insurer.

China Approves AUSTEDO® For Treating Chorea Associated with Huntington's Disease and Tardive Dyskinesia in Adults

Retrieved on: 
Monday, May 18, 2020
Health, Pharmaceutical, Branches of biology, Organ systems, Nervous system, Neurological disorders, Amphetamine, Huntington's disease, Tardive dyskinesia, Neurotransmitter transporters, Deutetrabenazine, Teva Pharmaceutical Industries, Vesicular monoamine transporter, Movement disorders, Huntington's Disease, Tardive Dyskinesia, AUSTEDO® (deutetrabenazine), Teva

This is the second approval and expected launch in China of a Teva specialty medicine, following the recent launch of TREANDA.

Key Points: 
  • This is the second approval and expected launch in China of a Teva specialty medicine, following the recent launch of TREANDA.
  • The approval of AUSTEDO in China is an exciting milestone for Teva," said Gianfranco Nazzi, Executive Vice President, International Markets, at Teva.
  • Tardive dyskinesia is a movement disorder characterized by repetitive and uncontrollable movements of the tongue, lips, face, trunk and extremities.
  • AUSTEDO is a vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. Food and Drug Administration for the treatment of tardive dyskinesia in adults and for the treatment of chorea associated with Huntingtons disease.

Neurocrine Biosciences to Present Data from its Movement Disorder Portfolio on the American Academy of Neurology Science Highlights Platform

Retrieved on: 
Wednesday, May 13, 2020
Branches of biology, Amphetamine, Biogenic amines, Neurotransmitter transporters, Receptors, Signal transduction, Neurocrine Biosciences, Neurocrine, Tardive dyskinesia, Dopamine, Vesicular monoamine transporter 2, Vesicular monoamine transporter

SAN DIEGO, May 13, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that multiple scientific presentations and abstracts from its movement disorder programs will be available on the 2020 American Academy of Neurology (AAN) Annual Meeting Science Highlights Platform beginning May 18, 2020.

Key Points: 
  • SAN DIEGO, May 13, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that multiple scientific presentations and abstracts from its movement disorder programs will be available on the 2020 American Academy of Neurology (AAN) Annual Meeting Science Highlights Platform beginning May 18, 2020.
  • "We look forward to presenting data from our movement disorder programs for tardive dyskinesia and Parkinson's disease at the AAN Science Highlights platform," said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences.
  • In patients with TD, these treatments are thought to result in irregular dopamine signaling in a region of the brain that controls movement.
  • VMAT2 is a protein in the brain that packages neurotransmitters, such as dopamine, for transport and release from presynaptic neurons.

Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders®

Retrieved on: 
Tuesday, September 17, 2019
Branches of biology, Amphetamine, Neurotransmitter transporters, Biogenic amines, Receptors, Signal transduction, Vesicular monoamine transporter 2, Vesicular monoamine transporter, Dopamine, Neurotransmitter, Neuron, Parkinson's disease

The data will be presented at the 2019 International Congress of Parkinson's Disease and Movement Disorders in Nice, France, Sept. 22-26, 2019.

Key Points: 
  • The data will be presented at the 2019 International Congress of Parkinson's Disease and Movement Disorders in Nice, France, Sept. 22-26, 2019.
  • "These data add to our understanding of these debilitating movement disorders that can place a substantial burden on the lives of patients."
  • In patients with TD, these treatments are thought to result in irregular dopamine signaling in a region of the brain that controls movement.
  • VMAT2 is a protein in the brain that packages neurotransmitters, such as dopamine, for transport and release in presynaptic neurons.

Thrivee Announces the Commencement of Services for Opioid Use Disorder in New Hampshire

Retrieved on: 
Thursday, August 29, 2019
Branches of biology, RTT, Biochemistry, Substance dependence, Opioid use disorder, Opioid, Vesicular monoamine transporter

NEW YORK, Aug. 29, 2019 /PRNewswire-PRWeb/ --Thrivee, Inc. announced today that the company will begin providing treatment services for Opioid Use Disorder for people living in New Hampshire beginning in September.

Key Points: 
  • NEW YORK, Aug. 29, 2019 /PRNewswire-PRWeb/ --Thrivee, Inc. announced today that the company will begin providing treatment services for Opioid Use Disorder for people living in New Hampshire beginning in September.
  • Thrivee's Virtual Medication Assisted Treatment (vMAT) program is a fully integrated approach to treating those suffering from Opioid Use Disorder.
  • Dave Henderson, CEO of Thrivee, said regarding the expansion, "We are incredibly excited to bring the benefits of the Thrivee vMAT program and platform to the people of New Hampshire.
  • Our singular passion is helping people affected by Opioid Use Disorder and humanizing their treatment.

Proton Partners International Limited, UK, Places Order on Treatment Planning System RayStation

Retrieved on: 
Friday, May 24, 2019
Radiation therapy, Branches of biology, Medical physics, Medicine, Radiation treatment planning, Pencil, Vesicular monoamine transporter, Pencil-beam scanning, RaySearch Laboratories

The decision to place an order on RayStation was made to further enhance the clinic's treatment planning potential.

Key Points: 
  • The decision to place an order on RayStation was made to further enhance the clinic's treatment planning potential.
  • RayStation was selected based on its advanced treatment planning functions for PPI's treatment modalities across its UK network of centres.
  • The order contains features such as proton pencil beam-scanning, fallback planning, multi-criteria optimization, adaptive planning and 3D, IMRT- and VMAT photon planning.
  • The company markets the RayStation treatment planning system and RayCare*, the next-generation oncology information system, worldwide.

Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2018 Net Product Sales Results and 2019 Program Milestones

Retrieved on: 
Sunday, January 6, 2019
Neuroscience, Biochemistry, Biology, Amphetamine, Biogenic amines, Neurotransmitter transporters, Receptors, Signal transduction, Neurocrine Biosciences, Valbenazine, Vesicular monoamine transporter 2, Vesicular monoamine transporter

"Our fourth quarter and 2018 results reflect the dedication of our team in educating healthcare providers about tardive dyskinesia and the benefit INGREZZA can bring to patients.

Key Points: 
  • "Our fourth quarter and 2018 results reflect the dedication of our team in educating healthcare providers about tardive dyskinesia and the benefit INGREZZA can bring to patients.
  • VMAT2 is a protein in the brain that packages neurotransmitters, such as dopamine, for transport and release in presynaptic neurons.
  • Neurocrine Biosciences, a San Diego based biopharmaceutical company, is focused on developing treatments for neurological and endocrine related disorders.
  • Neurocrine disclaims any obligation to update the statements contained in this press release after the date hereof.